Oxford BioMedica (OXBDF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst James Orsborne from Stifel Nicolaus reiterated a Buy rating on the stock and has a p500.00 price target.
James Orsborne has given his Buy rating due to a combination of factors that highlight Oxford BioMedica’s promising growth trajectory and financial outlook. The company reported a significant 44% revenue growth for 2024, aligning with its previous guidance and demonstrating strong performance in a challenging economic environment. This growth, coupled with a projected revenue increase of around 28% for 2025, underscores the company’s potential to capture future opportunities in the cell and gene therapy (CGT) sector.
Furthermore, Oxford BioMedica is on track to achieve profitability at the EBITDA level by 2025, with expectations of operating EBITDA margins exceeding 20% by the end of 2026. Despite the current macroeconomic uncertainties and tight funding conditions, the company’s 1.5x 2025 EV/sales multiple appears attractive, especially after a period of share price weakness. These factors collectively support the Buy rating, as they present a compelling entry point for investors seeking exposure to the CGT market.